TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07725796: A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

Sponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,130,976

Unlock Full NCT07725796 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07725796 Rescue Dossier →